Global Multiple Sclerosis Drug Market Trends, Forecast Report 2025-2037
Multiple Sclerosis Drug Market size is projected to grow from USD 25.07 billion to USD 42.07 billion, demonstrating a CAGR of over 4.2% during the forecast timeline, between 2025 and 2037. In the year 2025, the industry size of multiple sclerosis drug is evaluated at USD 25.89 billion.
The market growth is primarily driven by rising number of new drug candidates for multiple sclerosis being developed and pre-clinical trials are ongoing. Worldwide, nearly 3 million people are living with multiple sclerosis. Therefore, an increase in the number of sclerosis patients is expected to result in a rise in the need for medications and medical care.
The efficacy of the medicines and surging development in the treatment of multiple sclerosis will boost the global multiple sclerosis drug market growth. In June 2021, Bristol Myer Squibb released the progressive result of the early Zepsosia treatment, nearly, 80% of patients with high thalamic volume benefitted from the drug. Furthermore, proactive government efforts for multiple sclerosis patients are expected to propel the market growth.
Multiple Sclerosis Drug Sector: Growth Drivers and Challenges
Growth Drivers
- Higher Number of People Suffering from Multiple Sclerosis - MS (Multiple Sclerosis) occurs at any age, the initial range is most often between the ages of 20 and 40. However, individuals of various ages are affected. The prevalence of multiple sclerosis has increased worldwide. According to the National Library of Medicine, the prevalence of sclerosis is 35.9 per 100,000 people and 2.8million people are suffering from multiple sclerosis in 2020.
- Government Support for the Sclerosis Patient - With the rising number of sclerosis patients, the government has come forward to aid the treatment of the patients. Under the Anuyatra project launched by the Kerala government, India, the government has sanctioned nearly USD 116 thousand for the treatment of sclerosis. Moreover, in 2021, the 4 nations of the United Kingdom launched a Rare Disease Action Plan to address all rare diseases including multiple sclerosis.
- Growing Research and Development in the Treatment of Sclerosis – Owing to the exceptional research, the development in sclerosis diagnosis, drugs, and treatment is incessantly rising. For instance, Adamas Pharmaceuticals, Inc., has announced the beginning of phase 3 of the safety and efficiency of ADS-5102 in patients with multiple sclerosis and walking impairment.
- Rapid Growth of the Healthcare Sector - Healthcare sector was always a booming sector and it has been further loaded after the onset of COVID-19. The exigency of good healthcare facilities has aided its growth. According to the World Economic Forum, in 2021, USD 44 billion of the fund was raised for health innovation.
- Increasing Prevalence of Multiple Sclerosis Among Women - Women are more prone to multiple sclerosis. More women are diagnosed with sclerosis than men. The ratio of men and women with multiple sclerosis is 1:4.
Challenges
- Expensive Treatment and Drugs of Multiple Sclerosis - The cost of treatment and drugs is a big hindrance to the multiple sclerosis drug market growth. Despite of government’s proactive actions for the progress of multiple sclerosis treatment. The high price of medicines fails to suffice the needs of the market. Depending on the patient's age and gender, the cost of an MS (Multiple Sclerosis) disease-modifying therapy ranged from USD 57,202 to USD 92,719 per year.
- Shortage of Skilled Professionals & Lack of Healthcare Infrastructure
- Difficulty in Developing Drugs due to Unidentified Etiology of the Disease
Multiple Sclerosis Drug Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.2% |
|
Base Year Market Size (2024) |
USD 25.07 billion |
|
Forecast Year Market Size (2037) |
USD 42.07 billion |
|
Regional Scope |
|
Multiple Sclerosis Drug Segmentation
Medication Type (Oral, Injection)
The oral segment is expected to hold largest market share by the end of 2037, owing to its better efficacy and favorable safety profile against other available treatments. Most oral MS therapies currently on the market have been granted marketing approvals by regulatory agencies. For instance, Cipla Inc. received approval from the United States Food and Drug Administration for Tecfidera (dimethyl fumarate DR capsules), an oral drug to treat the relapsing forms of multiple sclerosis.
Our in-depth analysis of the global market includes the following segments:
|
By Drug |
|
|
By Type |
|
|
By Medication Type |
|
|
By Treatment |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMultiple Sclerosis Drug Industry - Regional Synopsis
The North America multiple sclerosis drug market is predicted to dominate majority revenue share by the end of 2037. A few variables that are anticipated to drive the expansion of the market in North America include an increase in the global burden of multiple sclerosis among the population and a higher probability of women getting multiple sclerosis.
In the United States, every week, around 200 new cases are added to the list of multiple sclerosis patients. Moreover, in 2019, nearly 400,000 people were affected by it. In North America, there are around 140 cases per 100,000 population and out of them, about 70% of patients are women, further, in the past 30 years, the ratio of women to men has jumped from 2:1 to 3:1. Furthermore, the development in the healthcare sector in North America will fuel the market growth. At the end of 2019, the total expenditure on health facilities in the U.S. was worth nearly 18% of the U.S. gross domestic product (GDP), and it is expected to total USD 6 trillion annually by 2028.
Companies Dominating the Multiple Sclerosis Drug Landscape
- Biogen
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- Merck KGaA.
- Janssen Pharmaceuticals Companies of Johnson & Johnson
- Bristol-Myers Squibb Company
- Cipla Inc.
In the News
- Janssen Pharmaceutical Companies announced the approval of PONVORY by the U.S. Food and Drug Administration. Ponvory is an oral medication used for treating adults with relapsing multiple Sclerosis.
-
Biogen collaborated with Eisai Co., Ltd., for the co-promotion of multiple sclerosis treatments including Tecfidera, Tysabri, and Avonex in Japan.
Author Credits: Radhika Pawar
- Report ID: 1986
- Published Date: Jan 28, 2025
- Report Format: PDF, PPT
